(Q24651938)

English

Denosumab

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Denosumab (English)

0 references

author name string

Steven C Pageau

1

0 references

language of work or name

0 references

publication date

2009

1 reference

Monoclonal Antibodies

0 references

1

0 references

3

0 references

210-5

0 references

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

7 April 2017

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

7 April 2017

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

7 April 2017

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

7 April 2017

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

28 September 2017

Bone resorption predicts for skeletal complications in metastatic bone disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

28 September 2017

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

28 September 2017

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

30 May 2018

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726593

28 November 2018

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8592

21 January 2018

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20065634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/MABS.1.3.8592

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24651938&oldid=1973259713"